Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
Genentech
Hoffmann-La Roche
International Drug Development Institute (IDDI)
Information provided by:
National Surgical Adjuvant Breast and Bowel Project (NSABP)
ClinicalTrials.gov Identifier:
NCT00365417
First received: August 15, 2006
Last updated: August 18, 2010
Last verified: August 2010
  Purpose

Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy drugs kill cancer cells more directly. This study will evaluate:

  • How bevacizumab, given with chemotherapy before surgery, and then bevacizumab given alone after surgery, will affect locally advanced breast tumors
  • Side effects from adding bevacizumab to chemotherapy
  • Whether adding bevacizumab to chemotherapy for breast cancer will affect the heart
  • If receiving bevacizumab will have any effect on how patients recover from surgery
  • Side effects of the combinations of drugs used in this study

Condition Intervention Phase
Breast Cancer
Drug: Bevacizumab
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Capecitabine
Drug: Docetaxel
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Clinical Trial of Bevacizumab Beginning Concurrently With a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy Followed by Postoperative Bevacizumab Alone for Women With Locally Advanced Breast Cancer

Resource links provided by NLM:


Further study details as provided by National Surgical Adjuvant Breast and Bowel Project (NSABP):

Primary Outcome Measures:
  • Pathologic Complete Response (pCR) in the Breast [ Time Frame: Assessed at the time of surgery ] [ Designated as safety issue: No ]
    Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen


Secondary Outcome Measures:
  • pCR in the Breast and Nodes [ Time Frame: Assessed at the time of surgery ] [ Designated as safety issue: No ]
    Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel nodes

  • Clinical Response Rate (cRR) of the Sequential Regimen [ Time Frame: Assessments at baseline, between the two chemotherapy regimens and following the last cycle of chemotherapy (before surgery) ] [ Designated as safety issue: No ]
    Measured by physical exam of the breast and axilla

  • Reported Adverse Events [ Time Frame: Assessments throughout; final adverse event assessment is 30 days after the last dose of bevacizumab ] [ Designated as safety issue: Yes ]
  • Cardiac Events [ Time Frame: Assessments throughout; up to 18 months following study entry ] [ Designated as safety issue: Yes ]
    Events: Congestive Heart Failure; Cardiac Death

  • Progression-free Survival [ Time Frame: From the first dose of study therapy until the date of disease progression or for a maximum of 24 months from study entry ] [ Designated as safety issue: No ]
    Time from the first dose of study therapy to disease progression

  • Overall Survival [ Time Frame: From the first dose of study therapy until the date of death or for a maximum of 24 months from study entry ] [ Designated as safety issue: No ]
    Time from the first dose of study therapy until date of death

  • Percentage of Surgical Complications Defined as Wound Dehiscence, Infection, Seroma, Hematoma [ Time Frame: Two (2) years ] [ Designated as safety issue: Yes ]

Enrollment: 45
Study Start Date: August 2006
Study Completion Date: November 2009
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Bevacizumab
    15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
    Other Name: Avastin
    Drug: Doxorubicin
    60 mg/m^2 IV every 21 days x 4 cycles
    Drug: Cyclophosphamide
    600 mg/m^2 IV every 21 days x 4 cycles
    Drug: Capecitabine
    Following clinical response assessment, 650 mg/m^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
    Other Name: Xeloda
    Drug: Docetaxel
    Following clinical response assessment, 75 mg/m^2 IV every 21 days x 4 cycles
    Other Name: Taxotere
Detailed Description:

Initial trials of neoadjuvant chemotherapy administered for locally advanced tumors, including those in breast cancer, demonstrated therapy could induce sufficient tumor regression to allow for the resection of otherwise unresectable tumors. Subsequent demonstration of the equivalence of lumpectomy to mastectomy in patients with operable breast cancer, stimulated interest in the concept of using preoperative chemotherapy to reduce large, but operable, primary tumors to allow for lumpectomy in women who would otherwise require a mastectomy. Given the data from previous studies, it is appropriate to continue development of sequential doxorubicin/cyclophosphamide/docetaxel regimens to improve on clinical and pathologic response rates. FB-4 is a Phase II, single arm study for women with locally advanced human epidermal growth factor receptor 2 (HER2)-negative breast cancer diagnosed by core needle biopsy. The primary aim of the study is to determine the pathologic complete response rate in the breast following neoadjuvant chemotherapy combined with bevacizumab.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must be female.
  • The patient must be greater than/equal to 18 years old
  • The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or limited incisional biopsy.
  • Patients must have clinical Stage IIIA, IIIB, or IIIC disease (American Joint Committee on Cancer [AJCC] staging criteria) with a primary breast tumor that is greater than/equal to 2.0 cm measured by clinical exam, unless the patient has inflammatory breast carcinoma, in which case measurable disease is not required.
  • Patients must have the ability to swallow oral medication.
  • The patient's Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1.
  • At the time of study entry, blood counts must meet the following criteria:

    • Absolute neutrophil count (ANC) must be greater than/equal to 1200/mm3.
    • Platelet count must be greater than/equal to 100,000/mm^3.
    • Hemoglobin must be greater than/equal to 10 g/dL.
  • The following criteria for evidence of adequate hepatic function must be met:

    • total bilirubin must be less than/equal to upper limit of normal (ULN) for the lab unless the patient has a grade 1 bilirubin elevation (greater than ULN to 1.5 x ULN) due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and
    • alkaline phosphatase must be less than 2.5 x ULN for the lab; and
    • aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab.
    • Alkaline phosphatase and AST may not both be greater than the ULN. For example, if the alkaline phosphatase is greater than the ULN but less than/equal to 2.5 x ULN, then the AST must be less than/equal to the ULN. If the AST is greater than the ULN but less than/equal to 1.5 x ULN, then the alkaline phosphatase must be less than/equal to ULN.
  • Patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than/equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan or positron emission tomography (PET) scan does not demonstrate metastatic disease. Patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are confirmed as benign by x-ray, magnetic resonance imaging (MRI), or biopsy.
  • Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], MRI, or PET scan) does not demonstrate metastatic disease and adequate hepatic function.
  • The following criteria for evidence of adequate renal function must be met:

    • Serum creatinine less than/equal to ULN for the lab.
    • Calculated creatinine clearance must be greater than 50 mL/min.
  • Urine protein/creatinine (UPC) ratio must be less than 1.0.
  • Patients must have their left ventricular ejection fraction (LVEF) assessed by multigated acquisition (MUGA) scan or echocardiogram within 3 months prior to study entry. The LVEF must be greater than/equal to the lower limit of normal (LLN) for the cardiac imaging facility performing the MUGA scan or echocardiogram. Note: If the cardiac imaging facility cannot provide a LLN, use 50% as the LLN value.

Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments to determine if bevacizumab therapy can be continued following doxorubicin and cyclophosphamide (AC) and postoperatively, it is critical that this baseline study be an accurate assessment of the patient's LVEF. If the baseline LVEF is greater than 65%, the MUGA scan or echocardiogram must be repeated prior to study entry. The lower of the two LVEF values should be used as the baseline LVEF.

  • Patients must have an electrocardiogram (EKG) within 3 months prior to study entry.

Exclusion Criteria:

  • Tumor determined to be strongly HER2-positive by immunohistochemistry (3+) or by fluorescent in situ hybridization (positive for gene amplification).
  • Excisional biopsy for this primary tumor.
  • Synchronous bilateral invasive breast cancer.
  • Surgical axillary staging procedure prior to study entry (Exceptions: 1) fine needle aspiration (FNA) of an axillary node is permitted for any patient, and 2) although not recommended, a sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted.)
  • History of any of the following cancers:

    • Ipsilateral breast cancer: invasive, ductal carcinoma in situ (DCIS) treated with any therapy other than excision
    • Contralateral breast cancer: invasive within the past 5 years (Patients with history of DCIS or synchronous DCIS are eligible)
    • History of non-breast malignancies within the 5 years prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the previous 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
  • Prior therapy with anthracyclines, taxanes, capecitabine, or bevacizumab for any malignancy.
  • Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to study entry. The only exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before study entry. In such a case, hormonal therapy must stop at or before study entry and be re-started, if indicated, following chemotherapy.
  • Any of the following cardiac conditions:

    • angina pectoris that requires the use of anti-anginal medication;
    • history of documented congestive heart failure;
    • serious cardiac arrhythmia requiring medication;
    • severe conduction abnormality;
    • valvular disease with documented cardiac function compromise; or
    • uncontrolled hypertension defined as blood pressure greater than 150/90 on antihypertensive therapy. (Patients with hypertension that is well controlled on medication are eligible.)
  • History of myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function.
  • History of transient ischemic attack (TIA) or cerebrovascular accident (CVA).
  • History of other arterial thrombotic event within 12 months before study entry.
  • Symptomatic peripheral vascular disease.
  • Any significant bleeding within 6 months before study entry.
  • Serious or non-healing wound, skin ulcers, or bone fracture.
  • Gastroduodenal ulcer(s) determined by endoscopy to be active.
  • Invasive procedures defined as follows:

    • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to planned start of study therapy. (Note: Placement of a vascular access device is not considered a major surgical procedure.)
    • Anticipation of need for major surgical procedures (other than the required breast surgery) during the course of the study.
  • Known bleeding diathesis or coagulopathy. (Patients on warfarin with an in-range international normalized ratio [INR] [usually between 2 and 3] are eligible.)
  • Other nonmalignant systemic disease (cardiovascular, renal, hepatic, diabetes, etc.) that would preclude the patient from receiving study treatment or would prevent required follow-up.
  • Sensory/motor neuropathy greater than/equal to grade 2, as defined by the NCI's Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0).
  • Conditions that would prohibit administration of corticosteroids.
  • History of hypersensitivity reaction to drugs formulated with polysorbate 80.
  • Therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention. Patients are eligible only if these medications are discontinued prior to study entry.
  • Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. These patients are eligible if this therapy is discontinued prior to study entry. (Women of reproductive potential must agree to use an effective non-hormonal method of contraception during study therapy and for at least 3 months after completion of bevacizumab.)
  • Pregnancy or lactation at the time of study entry.
  • Use of any investigational agent within 4 weeks prior to enrollment in the study.
  • Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00365417

Locations
United States, Pennsylvania
NSABP Foundation, Inc.
Pittsburgh, Pennsylvania, United States, 15212
Sponsors and Collaborators
National Surgical Adjuvant Breast and Bowel Project (NSABP)
Genentech
Hoffmann-La Roche
International Drug Development Institute (IDDI)
Investigators
Principal Investigator: Norman Wolmark, MD NSABP Foundation, Inc.
  More Information

No publications provided

Responsible Party: Norman Wolmark, MD, NSABP Foundation, Inc.
ClinicalTrials.gov Identifier: NCT00365417     History of Changes
Other Study ID Numbers: NSABP FB-4
Study First Received: August 15, 2006
Results First Received: August 21, 2009
Last Updated: August 18, 2010
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board
Canada: Health Canada
Canada: Ethics Review Committee

Keywords provided by National Surgical Adjuvant Breast and Bowel Project (NSABP):
NSABP
Doxorubicin
Cyclophosphamide
Bevacizumab
Capecitabine
Docetaxel
Breast cancer
Locally advanced
Neoadjuvant
Locally advanced breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Cyclophosphamide
Fluorouracil
Docetaxel
Capecitabine
Bevacizumab
Doxorubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Antimetabolites, Antineoplastic
Antimetabolites
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors

ClinicalTrials.gov processed this record on April 17, 2014